Mar. 21 at 8:38 PM
$SPRY $AXSM $ASTS $GSAT $RKLB (NASDAQ) — This isn’t a donation or a casino bet… it’s a once-in-a-lifetime setup 🧨 (currently
$8/share Roth initiated Price Target
$40)
Only globally approved, needle-free EpiPen epinephrine alternative → protected through 2039
Millions face life-threatening anaphylaxis daily → this replaces the needle
~22M+ shares short / ~45–48% of float → extreme positioning + fuel
20+ days to cover → pressure builds if demand accelerates
$72.2M year-one U.S. revenue → demand is real
22,500+ prescribers, ~50% repeat → refill engine starting
2026 = shift to renewals → compounding revenue begins
$84.3M FY revenue +
$28.1M Q4 → acceleration underway
Global rollout: EU, China, Australia → Canada next
~90% real-world success (single dose) → clinically validated
9,000+ schools onboarded → embedded distribution channel
$0 copay + expanding coverage → unlocking mass adoption
DTC + direct access → removing friction, scaling fast
Sales force expanding → deeper penetration in 2026
$245M cash → runway to breakeven
Urticaria pipeline → platform upside
ALK partnership → global scale leverage
Full details:
https://www.globenewswire.com/news-release/2026/03/09/3251623/0/en/ARS-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Updates-on-neffy-epinephrine-nasal-spray-Commercialization.html
Learn more about neffy:
http://neffy.com/about/
Global partner (ALK):
http://alk.net/our-solutions
Bottom line: De-risked, commercial-stage biotech with scaling adoption, global tailwinds, and a compounding revenue model 🔥
